Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Targets 'Obesity Disease Market' Despite Commercial Doubts

Executive Summary

Novo Nordisk is targeting obesity as a key disease market, but its CEO says global alliances are needed in future to help fight the global pandemic, including the food industry.

You may also be interested in...



"Synergy Search" Lies Behind AZ's Combined CV, Diabetes and Renal Ops

The head of AstraZeneca's newly combined cardiovascular, metabolic diseases and renal franchise says his mission is to align and find synergies for the three therapeutic areas.

SwedenBio Snapshot Shows Vibrant Ecosystem

Sweden´s ecosystem for drug discovery and development is flourishing, seeded by academia, nurtured by incubators and funded from varied sources, 2020 report shows.

Job Cuts As Nordic Nanovector Extends Cash Runway

Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.

Topics

Related Companies

UsernamePublicRestriction

Register

MT126735

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel